A means of closely monitoring localized (early) prostate cancer, but not providing treatment unless there are changes in the prostate specific antigen and/or other test results that show that the disease is getting worse.
Published in Chapter:
The Role of E-Health Interventions in Improving Clinical Outcomes and Overall Health for Prostate Cancer Patients: A Review
Donovan Anthony McGrowder (Faculty of Medical Sciences, The University of the West Indies, Jamaica), Fabian G. Miller (Faculty of Education, The Mico University College, Jamaica), Jabari G. Brown (Faculty of Medical Sciences, The University of the West Indies, Jamaica), Cameil Wilson-Clarke (Faculty of Medical Sciences, The University of the West Indies, Jamaica), and Lennox Anderson-Jackson (Faculty of Medical Sciences, The University of the West Indies, Jamaica)
Copyright: © 2021
|Pages: 28
DOI: 10.4018/978-1-7998-6527-8.ch007
Abstract
Globally, prostate cancer is a major healthcare problem. It is among the most frequently diagnosed malignancies and is the primary cancer in males in North America and the Caribbean, Europe, and some parts of Africa. Mobile health interventions afford prostate cancer patients in following prostate specific antigen results including trends, getting a better understanding of the severity of their disease and evaluate carefully the benefits and risks of the available treatment options. This review will examine the use of mobile health applications in prostate cancer research particularly in (1) clinical decision of selecting best treatment option or active surveillance, (2) monitoring disease- and treatment-related symptoms, (3) oncological and supportive care, (4) treatment decisions, and (5) health literacy and promotion of physical exercise. The benefits of telemedicine are discussed. Challenges will be examined and recommendations given for the development and efficient use of mobile health applications by prostate cancer patients and healthcare providers.